AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10698243 — intervention group
Group type: EXPERIMENTAL
Intervention: Any of the interventions (Groups A, B, C)
Number of subjects: 1227
Study 9120965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical morphine 0.05 mg/ml
Number of subjects: 52
Study 9120965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical morphine 0.375 mg/ml
Number of subjects: 52
Study 9120965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical morphine 0.5 mg/ml
Number of subjects: 52
Study 9120965 — intervention group
Group type: COMPARATOR
Intervention: Control group (no morphine infusion)
Number of subjects: 52
Study 8439215 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT emulsion
Number of subjects: 18
Study 8439215 — intervention group
Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 18
Study 3531226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-recombinant influenza A/California/10/78 (H1N1) (CR37)
Number of subjects: 40
Study 3531226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-recombinant influenza A/Washington/897/80 (H3N2) (CR48)
Number of subjects: 40
Study 3531226 — intervention group
Group type: COMPARATOR
Intervention: Inactivated trivalent influenza virus vaccine (administered parenterally)
Number of subjects: 40
Study 30068630 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5-lb weight stimulus
Number of subjects: 36
Study 30068630 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-lb weight stimulus
Number of subjects: 36
Study 30068630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30068630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-lb weight stimulus
Number of subjects: 36
Study 26845739 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086
Number of subjects: 5712
Study 26845739 — intervention group
Group type: COMPARATOR
Intervention: HAV/saline
Number of subjects: 5712
Study 23560678 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐PTFE membrane (test)
Number of subjects: 23
Study 23560678 — intervention group
Group type: COMPARATOR
Intervention: e‐PTFE membrane (control)
Number of subjects: 23
Study 23560678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both d‐PTFE and e‐PTFE membranes
Number of subjects: 23
Study 22389254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (CD20 mAb; dose 1, 300 mg and doses 2-8, 500 or 1000 mg)
Number of subjects: 116
Study 22389254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (CD20 mAb)
Number of subjects: 116
Study 20039397 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus MTX for 36 weeks
Number of subjects: 103
Study 20039397 — intervention group
Group type: COMPARATOR
Intervention: MTX alone for 12 weeks
Number of subjects: 103
Study 18533410 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrostimulation of the perineum (PESP)
Number of subjects: 18
Study 15777291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil (0.4 microg kg(‐1) PCA doses)
Number of subjects: 20
Study 15777291 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (50% inhaled)
Number of subjects: 20
Study 15777291 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference between remifentanil and nitrous oxide
Number of subjects: 20
Study 12548058 — intervention group
Group type: EXPERIMENTAL
Intervention: Viable Lactobacillus GG
Number of subjects: 35
Study 12548058 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated Lactobacillus GG
Number of subjects: 35
Study 12548058 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey formula (placebo group)
Number of subjects: 35
Study 10625166 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 24
Study 10625166 — intervention group
Group type: EXPERIMENTAL
Intervention: Bizzarri-Giuffrida laryngoscope
Number of subjects: 24
Study 10625166 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Vision Macintosh laryngoscope
Number of subjects: 24
Study 10625166 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiemers laryngoscope
Number of subjects: 24
Study 7730723 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg daily
Number of subjects: 12
Study 7730723 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg daily
Number of subjects: 12
Study 7730723 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg daily (after 5 months of treatment)
Number of subjects: 12
Study 7730723 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg daily for 5 months)
Number of subjects: 12
Study 2147912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 47
Study 2147912 — intervention group
Group type: COMPARATOR
Intervention: Astemizole
Number of subjects: 47
Study 32941 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral androgen (27 patients)
Number of subjects: 110
Study 32941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasmuscular androgen (23 patients)
Number of subjects: 110
Study 32941 — intervention group
Group type: EXPERIMENTAL
Intervention: No androgen (13 patients)
Number of subjects: 110
Study 32941 — intervention group
Group type: COMPARATOR
Intervention: Marrow transplantation (47 patients)
Number of subjects: 110
Study 32941 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (non-transplanted patients)
Number of subjects: 110
Study 31812585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastballs
Number of subjects: 12
Study 31812585 — intervention group
Group type: COMPARATOR
Intervention: Curveballs
Number of subjects: 12
Study 31812585 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 12
Study 30501389 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual physical therapy (3 sessions including desensitization maneuvers)
Number of subjects: 120
Study 30501389 — intervention group
Group type: COMPARATOR
Intervention: Surgery (decompression/release of the carpal tunnel)
Number of subjects: 120
Study 27190349 — intervention group
Group type: EXPERIMENTAL
Intervention: Research priorities identified through a national survey and workshop
Number of subjects: 439
Study 25529596 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A)
Number of subjects: 11499
Study 25529596 — intervention group
Group type: COMPARATOR
Intervention: Benazepril + Hydrochlorothiazide (B+H)
Number of subjects: 11499
Study 23997699 — intervention group
Group type: EXPERIMENTAL
Intervention: Swift FX nasal pillows
Number of subjects: 21
Study 23997699 — intervention group
Group type: COMPARATOR
Intervention: Nasal masks
Number of subjects: 21
Study 21982052 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention including oral and written explanations about cardiac rehabilitation, a follow-up telephone call, and a seminar for medical staff.
Number of subjects: 1024
Study 21982052 — intervention group
Group type: COMPARATOR
Intervention: Usual care without additional treatment.
Number of subjects: 1024
Study 19729418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (4 standard consultations over 12 weeks targeting change in nutrition, physical activity, and sedentary behaviour)
Number of subjects: 258
Study 19729418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 258
Study 19729418 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 258
Study 17760243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (16 mg IV before surgery, 8 mg at 12h and 24h postoperatively)
Number of subjects: 46
Study 17760243 — intervention group
Group type: COMPARATOR
Intervention: Morphine with PCA (Control Group M)
Number of subjects: 46
Study 15201414 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate
Number of subjects: 161
Study 15201414 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide
Number of subjects: 161
Study 15201414 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (all groups)
Number of subjects: 161
Study 15201414 — intervention group
Group type: COMPARATOR
Intervention: Control (methotrexate alone)
Number of subjects: 161
Study 14706898 — intervention group
Group type: EXPERIMENTAL
Intervention: Herceptin®
Number of subjects: 0
Study 14706898 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical studies (randomized trials, non-randomized studies, observational studies)
Number of subjects: 0
Study 14706898 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelization techniques
Number of subjects: 0
Study 10194739 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher methadone doses
Number of subjects: 265
Study 10194739 — intervention group
Group type: COMPARATOR
Intervention: Lower methadone doses
Number of subjects: 265
Study 10194739 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned therapist
Number of subjects: 265
Study 7554793 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual habituation study
Number of subjects: 0
Study 2258583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 500 mg
Number of subjects: 11
Study 2258583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6447999 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 89
Study 6447999 — intervention group
Group type: EXPERIMENTAL
Intervention: pyridoxine hydrochloride
Number of subjects: 89
Study 6447999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-hydroxytryptophan and pyridoxine
Number of subjects: 89
Study 6447999 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with moderate and severe congenital heart disease excluded)
Number of subjects: 89
Study 6447999 — intervention group
Group type: EXPERIMENTAL
Intervention: Various groups (including those whose parents complied with guidance)
Number of subjects: 89
Study 31300336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringing the bell on the final day of RT
Number of subjects: 210
Study 31300336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bell ringing)
Number of subjects: 210
Study 27840326 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY stent
Number of subjects: 263
Study 27840326 — intervention group
Group type: COMPARATOR
Intervention: PROMUS Element Plus stent
Number of subjects: 263
Study 25709055 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Exercise Therapy
Number of subjects: 30
Study 25709055 — intervention group
Group type: COMPARATOR
Intervention: Self-guided therapy
Number of subjects: 30
Study 24361543 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search attentional bias modification (ABM)
Number of subjects: 16
Study 24361543 — intervention group
Group type: COMPARATOR
Intervention: Control condition (placebo training versions)
Number of subjects: 16
Study 21724950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet form II of semagacestat (140 mg)
Number of subjects: 41
Study 21724950 — intervention group
Group type: EXPERIMENTAL
Intervention: Semagacestat (140 mg) administered fed or fasting
Number of subjects: 41
Study 21724950 — intervention group
Group type: EXPERIMENTAL
Intervention: Semagacestat (140 mg) at different times of dosing (morning fasting, evening fasting)
Number of subjects: 41
Study 19247233 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane
Number of subjects: 10
Study 19247233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid
Number of subjects: 10
Study 19247233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel
Number of subjects: 10
Study 19247233 — intervention group
Group type: COMPARATOR
Intervention: Standard plasters
Number of subjects: 10
Study 17222829 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed conjugated estrogen therapy (0.625 mg/d)
Number of subjects: 90
Study 17222829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/d)
Number of subjects: 90
Study 17222829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15703460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 50 mg intramuscularly twice weekly combined with erythropoietin (EPO) 1,000 U three times weekly
Number of subjects: 32
Study 15703460 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin (EPO) 1,000 U three times weekly
Number of subjects: 32
Study 12127032 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous morphine (CM) at 10 microg/kg/h intravenous infusion
Number of subjects: 181
Study 12127032 — intervention group
Group type: COMPARATOR
Intervention: Intermittent morphine (IM) at 30 microg/kg every 3 hours
Number of subjects: 181
Study 12127032 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous morphine (CM)
Number of subjects: 181
Study 12127032 — intervention group
Group type: COMPARATOR
Intervention: Intermittent morphine (IM)
Number of subjects: 181
Study 9612677 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization (TVP)
Number of subjects: 150
Study 9612677 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 150
Study 7753258 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (0.5 mmol/kg body weight)
Number of subjects: 0
Study 7753258 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate (0.5 mmol/kg body weight)
Number of subjects: 0
Study 7753258 — intervention group
Group type: COMPARATOR
Intervention: Time control group (no ion ingestion)
Number of subjects: 0
Study 31665733 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 7437
Study 31665733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7437
Study 28854065 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg twice daily on days 1 to 5) with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8 mg on days 2 to 4)
Number of subjects: 638
Study 28854065 — intervention group
Group type: COMPARATOR
Intervention: Placebo with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8 mg on days 2 to 4)
Number of subjects: 638
Study 27209526 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Skills Work (TSW)
Number of subjects: 54
Study 27209526 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Vocational Rehabilitation (E-VR)
Number of subjects: 54
Study 24606087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhIGF-I/rhIGFBP-3 (30 mg/d)
Number of subjects: 56
Study 24606087 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhIGF-I/rhIGFBP-3 (60 mg/d)
Number of subjects: 56
Study 24606087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21987363 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture anchor fixation
Number of subjects: 14
Study 21987363 — intervention group
Group type: COMPARATOR
Intervention: Screw fixation
Number of subjects: 14
Study 21987363 — intervention group
Group type: COMPARATOR
Intervention: Pull-out suture fixation
Number of subjects: 14
Study 19805678 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 802
Study 19805678 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 802
Study 16765234 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization
Number of subjects: 307
Study 16765234 — intervention group
Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 307
Study 16765234 — intervention group
Group type: EXPERIMENTAL
Intervention: CLI
Number of subjects: 307
Study 16765234 — intervention group
Group type: EXPERIMENTAL
Intervention: IC
Number of subjects: 307
Study 15628646 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient psychotherapeutic treatment with accompanying children
Number of subjects: 29
Study 15628646 — intervention group
Group type: COMPARATOR
Intervention: In-patient psychotherapeutic treatment without accompanying children
Number of subjects: 29
Study 11164146 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave treatment
Number of subjects: 52
Study 11164146 — intervention group
Group type: COMPARATOR
Intervention: Terazosin treatment
Number of subjects: 52
Study 9230157 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 40
Study 9230157 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 40
Study 9230157 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 81 mg
Number of subjects: 40
Study 9230157 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin 81 mg
Number of subjects: 40
Study 9230157 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 325 mg
Number of subjects: 40
Study 9230157 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin 325 mg
Number of subjects: 40
Study 8109281 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) in actively treated group A (12 patients)
Number of subjects: 24
Study 8109281 — intervention group
Group type: COMPARATOR
Intervention: Control group B (10 patients, received implantation after the study period)
Number of subjects: 24
Study 3630582 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 8
Study 3630582 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg/kg
Number of subjects: 8
Study 3630582 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.5 mg/kg
Number of subjects: 8
Study 3630582 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 8
Study 3630582 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (Midazolam or Diazepam)
Number of subjects: 8
Study 29050650 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF)
Number of subjects: 20
Study 29050650 — intervention group
Group type: COMPARATOR
Intervention: Control (standard supplement)
Number of subjects: 20
Study 27982267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 58
Study 27982267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 25262253 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (1.5 mg Slow Release (SR)/day)
Number of subjects: 56
Study 25262253 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg/d)
Number of subjects: 56
Study 24041245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed (adaptive working memory training)
Number of subjects: 126
Study 24041245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-adaptive version of Cogmed)
Number of subjects: 126
Study 20810085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 46
Study 20810085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19494558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy, details not specified
Number of subjects: 0
Study 19494558 — intervention group
Group type: COMPARATOR
Intervention: Surfactant replacement, 'kinder gentler' modes of ventilation, prenatal corticosteroids
Number of subjects: 0
Study 15904750 — intervention group
Group type: COMPARATOR
Intervention: Augmented intervention (e-mail reminder with provider prompts, patient education material, and clinical nurse specialist outreach)
Number of subjects: 673
Study 15904750 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention (one-time e-mail reminder highlighting six pain-specific clinical recommendations)
Number of subjects: 673
Study 15904750 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 673
Study 12456381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol challenge
Number of subjects: 50
Study 12456381 — intervention group
Group type: COMPARATOR
Intervention: Eucapnic voluntary hyperpnea (EVH) challenge
Number of subjects: 50
Study 10480154 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 16
Study 10480154 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate (CaCO3)
Number of subjects: 16
Study 8630574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 750 micrograms/d
Number of subjects: 21
Study 8630574 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 1,500 micrograms/d
Number of subjects: 21
Study 8630574 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 21
Study 8630574 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 21
Study 1672493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cromolyn sodium, 1 spray in each nostril QID for 4 weeks
Number of subjects: 79
Study 1672493 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terfenadine, 60 mg BID for 4 weeks
Number of subjects: 79
Study 1672493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cromolyn sodium
Number of subjects: 79
Study 1672493 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terfenadine
Number of subjects: 79
Study 1672493 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium and terfenadine
Number of subjects: 79
Study 7037487 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline (10 mg daily for two days plus a 4 mg dose 1 hour before the post-treatment test)
Number of subjects: 0
Study 7037487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7037487 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline
Number of subjects: 0
Study 31522355 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-supervised co-adaptive BCI
Number of subjects: 20
Study 31522355 — intervention group
Group type: COMPARATOR
Intervention: Supervised co-adaptive BCI
Number of subjects: 20
Study 27646499 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings on cigarette packs
Number of subjects: 112
Study 27646499 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings on cigarette packs
Number of subjects: 112
Study 24811201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (n=182)
Number of subjects: 257
Study 24811201 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (n=180)
Number of subjects: 257
Study 22732966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional guidance about diet and its relationship with disease, sources of nutrients, and reduction of dietary sodium and fats
Number of subjects: 46
Study 22732966 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46